ADVERSE DRUG REACTION

Cutaneous leucocytoclastic vasculitis associated with omeprazole

M Odeh, M Lurie, A Oliven

Omeprazole is a potent proton pump inhibitor and usually is well tolerated. Adverse effects of this drug have been reported in up to 5% of patients, most of which are trivial and disappear rapidly on discontinuation of the drug. Skin adverse reactions attributed to omeprazole are uncommon and include rashes, urticaria, angio-oedema, acute disseminated epidermal necrolysis, lichen spinulosus, and contact dermatitis. Cutaneous leucocytoclastic vasculitis (CLV) has not been previously reported in association with omeprazole. The development of CLV in an elderly patient four weeks after starting treatment with omeprazole is described.

CASE REPORT

A 71 year old woman was admitted with a two day history of palpable skin rash involving both hands and legs and the abdomen, and accompanied with pruritus. She denied fever, abdominal pain, or palpable skin rash involving the small blood vessels with polymorphonuclear leucocytes, and angiography. The patient had no further episodes of skin rash over a follow up period of four months; amiodarone and budesonide treatment continued. Rechallenge with omeprazole was not done for ethical reasons.

Four weeks previously she had started treatment with omeprazole, 20 mg daily for epigastric pain, which was considered by her family physician to be due to activation of her old duodenal ulcer. The patient's epigastric pain resolved within a few days after starting treatment with omeprazole and she continued ingestion of this drug. Her other medical history included bronchial asthma treated with a budesonide inhaler for the last few years, and paroxysmal atrial fibrillation treated with amiodarone for the last four months.

Physical examination revealed a normal body temperature and a regular heart rate with 72 beats/min. Heart and lung examination was normal, and no lymphadenopathy, hepatosplenomegaly, or abdominal tenderness were present. Skin examination revealed an erythematous macular, papular rash, 1–10 mm in diameter over both hands, thighs, and lower abdomen. The buttocks were not involved. Other physical findings were unremarkable.

Four weeks after starting treatment with omeprazole is the development of CLV in an elderly patient. Proton pump inhibitors, particularly omeprazole, are now among the most commonly prescribed drugs worldwide. Omeprazole induced vasculitis is probably rare. However, knowing that systemic vasculitides may also affect visceral organs and can be serious and life threatening, physicians should be aware of the possibility of this adverse reaction, in order to stop treatment with omeprazole early and prevent more serious complications.

DISCUSSION

CLV is an inflammatory vascular disease characterised by prominent involvement of the skin, and by the infiltration of the small blood vessels with polymorphonuclear leucocytes and the presence of leucocytoclasis (fragmentation of nuclei and formation of nuclear dust), and red blood cell extravasation, as was found in the skin biopsy from our

Learning point

Proton pump inhibitors, particularly omeprazole, are now among the most commonly prescribed drugs worldwide. Omeprazole induced vasculitis is probably rare. However, knowing that systemic vasculitides may also affect visceral organs and can be serious and life threatening, physicians should be aware of the possibility of this adverse reaction, in order to stop treatment with omeprazole early and prevent more serious complications.

Abbreviations: CLV, cutaneous leucocytoclastic vasculitis
Among the most commonly prescribed drugs worldwide, a variety of drugs have been reported to be associated with CLV and include penicillins, sulfonamides and other antibiotics, non-steroidal anti-inflammatory drugs, propylthiouracil, iodides, levamisole, anticonvulsants, and others. H₂-receptor antagonists have rarely been associated with hypersensitivity vasculitis, and to the best of our knowledge vasculitis of any type has not previously been reported in association with omeprazole or with any other proton pump inhibitor.

In the absence of any other known cause, development of the skin reaction four weeks after initiation with omeprazole treatment, and rapid reversal of it after withdrawal of the drug, the patient’s CLV could be attributed to omeprazole. Cutaneous vasculitis including CLV has been reported, however very rarely, in association with amiodarone. Development of the CLV in our patient four months after starting treatment with amiodarone, and its rapid resolution while treatment with amiodarone was continued, suggests that amiodarone is unlikely to be the cause of the CLV.

Omeprazole is usually well tolerated. Adverse effects of this drug have been reported in up to 5% of patients, most commonly headache, dizziness, diarrhoea, abdominal pain, and fatigue. There also have been rare reports of skin reactions, hepatic reactions, interstitial nephritis, agranulocytosis, optic neuritis, and anaphylaxis. Adverse reaction of the skin attributed to omeprazole include rashes, urticaria and angio-oedema, acute disseminated epidermal necrolysis, lichen spinulosus, and contact dermatitis.

Proton pump inhibitors, particularly omeprazole, are now among the most commonly prescribed drugs worldwide. Omeprazole induced vasculitis is probably rare. However, with the understanding that systemic vasculitides may also affect visceral organs and can be life threatening, physicians should be aware of this possibility of adverse reaction of omeprazole in order to stop treatment with the drug early, and to prevent more serious complications.

Authors’ affiliations
M Odeh, A Oliven, Department of Internal Medicine B, Bnai Zion Medical Center, and Technion Faculty of Medicine, Israel Institute of Technology, Haifa, Israel
M Lurie, Department of Pathology, Bnai Zion Medical Center, and Technion Faculty of Medicine, Israel Institute of Technology, Haifa, Israel

Correspondence and requests for reprints to: Dr Majed Odeh, PO Box 6477, Haifa 31063, Israel
Submitted 31 August 2000
Accepted 15 February 2001

REFERENCES

Cutaneous leucocytoclastic vasculitis associated with omeprazole

M Odeh, M Lurie and A Oliven

Postgrad Med J 2002 78: 114-115
doi: 10.1136/pmj.78.916.114

Updated information and services can be found at:
http://pmj.bmj.com/content/78/916/114

These include:

References
This article cites 16 articles, 2 of which you can access for free at:
http://pmj.bmj.com/content/78/916/114#BIBL

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections
Articles on similar topics can be found in the following collections

Immunology (including allergy) (396)
Dermatology (109)

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/